Fibroblast News and Research RSS Feed - Fibroblast News and Research

Fibroblasts are connective tissue cells which secrete an extracellular matrix rich in collagen and other macromolecules.
Researchers compare effectiveness of two stem cell types in treating retinal degeneration

Researchers compare effectiveness of two stem cell types in treating retinal degeneration

By growing two types of stem cells in a "3-D culture" and measuring their ability to produce retinal cells, a team lead by St. Jude Children's Research Hospital researchers has found one cell type to be better at producing retinal cells. [More]
First participant enrolled in RepliCel's RCT-01 Phase 1/2 clinical trial for treatment of chronic tendinosis

First participant enrolled in RepliCel's RCT-01 Phase 1/2 clinical trial for treatment of chronic tendinosis

RepliCel Life Sciences Inc., a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announced today that the first participant in its Phase 1/2 clinical trial of RCT-01, being tested for the treatment of chronic unilateral Achilles tendinosis, has been enrolled and their tissue biopsy sent for processing prior to intra-tendon ultrasound-guided injections. [More]
What do cells really look like in 3D?

What do cells really look like in 3D?

Nanolive SA, a start-up company founded in November 2013 at the EPFL Innovation Park in Lausanne, Switzerland, has developed a revolutionary microscope which allows for the very first time the exploration of a living cell in 3D without damaging it. [More]
Researchers explore the science of exosomes in heart repair

Researchers explore the science of exosomes in heart repair

A little more than a decade ago, researchers discovered that all cells secrete tiny communications modules jammed with an entire work crew of messages for other cells. Today, a team of researchers, led by stem cell researcher Raj Kishore, PhD, Director of the Stem Cell Therapy Program at the Center for Translational Medicine at Temple University School of Medicine, is harnessing the communications vesicles excreted by stem cells and using them to induce the damaged heart to repair itself. [More]
Lenvatinib-everolimus combination extends PFS in patients with mRCC versus everolimus alone

Lenvatinib-everolimus combination extends PFS in patients with mRCC versus everolimus alone

Eisai Inc. announced today results from an investigational Phase 2 trial which showed that lenvatinib, when used in combination with everolimus, significantly extended progression-free survival (PFS) in patients with metastatic renal cell carcinoma (mRCC) versus everolimus alone. [More]
Process of aging could be delayed in human cell lines

Process of aging could be delayed in human cell lines

Can the process of aging be delayed or even reversed? Research led by specially appointed Professor Jun-Ichi Hayashi from the University of Tsukuba in Japan has shown that, in human cell lines at least, it can. They also found that the regulation of two genes involved with the production of glycine, the smallest and simplest amino acid, is partly responsible for some of the characteristics of aging. [More]
Two grants to bolster research on why ovarian cancer is resistant to chemotherapy

Two grants to bolster research on why ovarian cancer is resistant to chemotherapy

Determining which strains of cancer will eventually become resistant to chemotherapy could be key in figuring out more effective and targeted forms of treatment. Finding the genes responsible for chemo-resistance is what Jeremy Chien, Ph.D., member of the Cancer Biology Program at The University of Kansas Cancer Center, is looking to do with an innovative system that draws inspiration from the early days of cancer gene research. [More]
Amgen announces AMG 416 Phase 3 results for treatment of secondary hyperparathyroidism in CKD patients

Amgen announces AMG 416 Phase 3 results for treatment of secondary hyperparathyroidism in CKD patients

Amgen today announced pooled data from two pivotal Phase 3, global, randomized, placebo-controlled trials evaluating AMG 416, a novel calcimimetic, for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease (CKD) receiving hemodialysis. [More]
Novel drug target identified for treating rheumatoid arthritis

Novel drug target identified for treating rheumatoid arthritis

Researchers at the La Jolla Institute for Allergy and Immunology, in collaboration with colleagues the University of California, San Diego, identified a novel drug target for the treatment of rheumatoid arthritis that focuses on the cells that are directly responsible for the cartilage damage in affected joints. [More]
Overview of Blueprint Medicines' kinase drug discovery strategy published in JCI

Overview of Blueprint Medicines' kinase drug discovery strategy published in JCI

Blueprint Medicines today announced that the Journal of Clinical Investigation published an overview of the Company's kinase drug discovery and development strategy. The publication underscores Blueprint Medicines' focus on identifying novel genomically defined disease drivers and the use of novel chemistry from its proprietary compound library to craft highly selective kinase inhibitors for new and difficult-to-drug kinase targets. [More]
Therapeutic candidate BLU-554 has significant anti-tumor activity in HCC models

Therapeutic candidate BLU-554 has significant anti-tumor activity in HCC models

Blueprint Medicines today announced new preclinical data demonstrating that BLU-554, a selective and potent inhibitor of fibroblast growth factor receptor 4 (FGFR4), has significant anti-tumor activity in models of hepatocellular carcinoma (HCC) that are dependent on FGFR4 signaling. [More]
Study identifies BLU-554 as potential treatment option for HCC patients

Study identifies BLU-554 as potential treatment option for HCC patients

Findings were presented today at The International Liver CongressTM 2015 on a novel therapeutic candidate for a genomically defined subset of hepatocellular carcinoma (HCC) patients with an aberrant fibroblast growth factor receptor 4 (FGFR4) pathway. [More]
FGF21 protein can boost regenerative effects of human PPARα

FGF21 protein can boost regenerative effects of human PPARα

Researchers at UC Davis have illuminated an important distinction between mice and humans: how human livers heal. The difference centers on a protein called PPARα, which activates liver regeneration. Normally, mouse PPARα is far more active and efficient than the human form, allowing mice to quickly regenerate damaged livers. [More]
Early response plus genetic variants strengthen antidepressant outcome prediction

Early response plus genetic variants strengthen antidepressant outcome prediction

Considering genetic variants in combination with early partial improvement could be useful for predicting antidepressant outcome, say researchers. [More]
Researchers develop new AFM system for imaging structural dynamics of living cells, neurons

Researchers develop new AFM system for imaging structural dynamics of living cells, neurons

While progress has been made over the past decades in the pursuit to optimize atomic force microscopy (AFM) for imaging living cells, there were still a number of limitations and technological issues that needed to be addressed before fundamental questions in cell biology could be address in living cells. [More]
Fat cell transplantation benefits systemic sclerosis patients with non-healing digital ulcers

Fat cell transplantation benefits systemic sclerosis patients with non-healing digital ulcers

Digital ulcers (DUs) are a frequent, painful, and quality of life altering complication for patients with systemic sclerosis (SSc), a connective tissue disease causing a progressive loss of small blood vessels and resulting changes in organs and tissues. DUs on the fingertips of SSc patients are slow to heal, if they heal at all, as many are unresponsive to any therapies. [More]
RepliCel submits CTA for RCS-01 study to treat patients suffering from aged, UV-damaged skin

RepliCel submits CTA for RCS-01 study to treat patients suffering from aged, UV-damaged skin

RepliCel Life Sciences Inc., a clinical stage regenerative medicine company focused on the development of autologous cell therapies, today announced the submission of a Clinical Trial Application (CTA) to the German Competent Authority, the Paul-Ehrlich-Institut (PEI), requesting clearance to initiate a Phase 1 clinical trial investigating the use of RCS-01 to treat patients suffering from aged and UV-damaged skin. [More]
Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC

Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC

Eisai Inc. announced today that the U.S. Food and Drug Administration approved the company's receptor tyrosine kinase inhibitor LENVIMA (lenvatinib) for the treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC). [More]
Researchers identify molecular pathways associated with distinct subsets of SSc patients

Researchers identify molecular pathways associated with distinct subsets of SSc patients

For years, doctors have been baffled about why some patients with systemic sclerosis (SSc) respond to therapy while others do not. [More]
Scientists identify new cellular pathway affected in cystinosis

Scientists identify new cellular pathway affected in cystinosis

Scientists at The Scripps Research Institute have identified a new cellular pathway that is affected in cystinosis, a rare genetic disorder that can result in eye and kidney damage. [More]
Advertisement
Advertisement